Podcast: Scrip’s Asia Team Dissects Pharma’s Response To Coronavirus
New Episode Looks At Drug, Vaccine Development
Executive Summary
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Featuring Brian Yang in Beijing, Vibha Ravi in Mumbai, Jung Won Shin in Seoul and Ian Haydock in Tokyo.
Topics covered include how local and foreign pharma firms in China are working to progress novel antivirals and how traditional medicines have found a role in the outbreak, Indian companies’ concerns over potential disruptions to API supplies from main supplier China, South Korean moves to address a spike in cases, and Japanese and multinational firms’ response. Also touching on what the impact might be on future R&D strategy.
01:30: China’s drug development efforts looking at antivirals, vaccines and TCMs.
07:20: India’s bulk supply concerns and what the industry is considering to diversify risk.
13:15: South Korea’s pharma industry and government are taking measured steps as the outbreak surges locally.
16:15: Japan’s pharma firms do not appear too concerned so far amid low exposure to China, while multinationals play wait and see over business impact/response.
(Rolling coverage of the outbreak and the biopharma industry's response is aggregated here.)